



NeonMind Retains Renmark Financial Communications Inc.

Vancouver, B.C. – February 3, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FRA: 6UF) (“**NeonMind**”), a psychedelic drug development company, is pleased to announce that it has retained the services of Renmark Financial Communications Inc. (“**Renmark**”) for certain investor relations activities.

“We are pleased to announce that we have selected Renmark to reinforce NeonMind's profile in the financial community and enhance the visibility of our company. We choose Renmark because its standards and methodologies fit well with the message we wish to communicate to the investing public,” noted Rob Tessarolo, NeonMind President & CEO.

Renmark is expected to supplement the existing investor relations program by including a focus on institutions and brokerage firms that will expand the target investor audience of the Company.

In consideration of the services to be provided, the monthly fees incurred by NeonMind will be a cash consideration of up to \$7,000 CAD, for a period of three months ending on April 7th, 2021, and monthly thereafter.

Renmark Financial Communications does not have any interest, directly or indirectly, in NeonMind its securities, or any right or intent to acquire such an interest.

About NeonMind Biosciences Inc.

NeonMind is a preclinical psychedelic drug development company. Its first proposed drug candidate involves the administration of psilocybin (a complex organic compound found in psychedelic mushrooms) as a treatment for obesity and related illnesses for which NeonMind is conducting a preclinical trial at the University of British Columbia. NeonMind has filed five U.S. provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity, and/or altering the diet of an individual by administering psilocybin and/or other psychedelic compounds or their analogues or by administering psilocybin or its analogue in conjunction with therapy or other treatments. NeonMind is also pursuing commercialization of its catalogue of proprietary medicinal mushroom product formulas. It recently launched a collection of four



mushroom-infused coffees containing medicinal mushrooms Lion's Mane, Turkey Tail, Reishi and Cordyceps which are available for purchase online in Canada at www.neonmind.com.

For more information on NeonMind, go to www.NeonMindBiosciences.com or buy NeonMind mushroom infused coffee at www.NeonMind.com.

Rob Tessarolo, President & CEO

rob@neonmind.com

Tel: 416-750-3101

Investor Relations:

Edge Communications

invest@neonmind.com

Tel: 1-866-318-6874

Renmark Financial Communications Inc.

Melanie Barbeau: `

mbarbeau@renmarkfinancial.com

Tel: 416-644-2020 or 212-812-7680

Media Inquiries:



Exvera Communications Inc.

brittany@exvera.com

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. The laws around cultivating, selling and using psychedelic mushrooms would need to change in most jurisdictions in order for the use of psychedelic products to be legal and sale of, and demand for NeonMind products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. NeonMind cautions readers not to place undue reliance on forward-looking statements provided by NeonMind, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and NeonMind expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.